LAZABEMIDE
| Title | Journal |
|---|---|
| Novel reversible monoamine oxidase A inhibitors: highly potent and selective 3-(1H-pyrrol-3-yl)-2-oxazolidinones. | Journal of medicinal chemistry 20111208 |
| Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia. | Journal of neural transmission (Vienna, Austria : 1996) 20111201 |
| Up-regulation of the isoenzymes MAO-A and MAO-B in the human basal ganglia and pons in Huntington's disease revealed by quantitative enzyme radioautography. | Brain research 20110125 |
| Combined treatment with MAO-A inhibitor and MAO-B inhibitor increases extracellular noradrenaline levels more than MAO-A inhibitor alone through increases in beta-phenylethylamine. | European journal of pharmacology 20100710 |
| Molecular dynamics, flexible docking, virtual screening, ADMET predictions, and molecular interaction field studies to design novel potential MAO-B inhibitors. | Journal of biomolecular structure & dynamics 20080201 |
| Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice. | Journal of neurochemistry 20060301 |
| Effect of co-administration of subchronic lithium pretreatment and acute MAO inhibitors on extracellular monoamine levels and the expression of contextual conditioned fear in rats. | European journal of pharmacology 20060227 |
| Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds. | Bioorganic & medicinal chemistry letters 20051015 |
| Characterisation of imidazoline I2 binding sites in pig brain. | European journal of pharmacology 20050905 |
| High-affinity binding of beta-carbolines to imidazoline I2B receptors and MAO-A in rat tissues: norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain. | European journal of pharmacology 20050822 |
| Monoamine oxidase B inhibitors for early Parkinson's disease. | The Cochrane database of systematic reviews 20050720 |
| Effects of depression, cigarette smoking, and age on monoamine oxidase B in amygdaloid nuclei. | Brain research 20050510 |
| Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway. | British journal of pharmacology 20041201 |
| Clinical trials of neuroprotection for Parkinson's disease. | Neurology 20041012 |
| SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile. | The Journal of pharmacology and experimental therapeutics 20040901 |
| Differential substrate specificity of monoamine oxidase in the rat heart and renal cortex. | Life sciences 20030711 |
| Serotonin transporter and MAO-B levels in monoamine nuclei of the human brainstem are normal in major depression. | Journal of psychiatric research 20030101 |
| Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation. | Addiction (Abingdon, England) 20021001 |
| Lifestyle drug market booming. | Nature medicine 20020901 |
| Inhibition of monoamine oxidase modulates the behaviour of semicarbazide-sensitive amine oxidase (SSAO). | Journal of neural transmission (Vienna, Austria : 1996) 20020301 |
| Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. | European journal of pharmacology 20010518 |
| Antioxidant activity of the monoamine oxidase B inhibitor lazabemide. | Biochemical pharmacology 20000901 |
| Safety study of lazabemide (Ro19-6327), a new MAO-B inhibitor, on cardiac arrhythmias and blood pressure of patients with Parkinson's disease. | Clinical neuropharmacology 19990101 |
| Increased density of catalytic sites and expression of brain monoamine oxidase A in humans with hepatic encephalopathy. | Journal of neurochemistry 19970301 |
| Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group. | Annals of neurology 19960701 |
| Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry. | Neuroscience 19960201 |
| Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. | Neuroscience 19940901 |
| Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings. | Journal of neural transmission. Supplementum 19940101 |
| Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327. | Neurology 19931001 |
| Ro 19-6327, a reversible and highly selective monoamine, oxidase B inhibitor: a novel tool to explore the MAO-B function in humans. | Advances in neurology 19900101 |